Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ArriVent BioPharma (AVBP) Change in Acquisitions & Divestments (2025 - 2026)

ArriVent BioPharma has reported Change in Acquisitions & Divestments over the past 2 years, most recently at $68.0 million for Q1 2026.

  • Quarterly results put Change in Acquisitions & Divestments at $68.0 million for Q1 2026, up 45.73% from a year ago — trailing twelve months through Mar 2026 was $223.0 million (changed N/A YoY), and the annual figure for FY2025 was $201.7 million, up 11772.04%.
  • Change in Acquisitions & Divestments reached $68.0 million in Q1 2026 per AVBP's latest filing, down from $80.0 million in the prior quarter.
  • Across five years, Change in Acquisitions & Divestments topped out at $80.0 million in Q4 2025 and bottomed at $35.5 million in Q2 2025.